BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ulotaront readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ulotaront\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07225712-857@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07225712)
DESCRIPTION:Ulotaront\, phase 3\, Schizophrenia.\nStudy: A Long-term Admini
 stration Trial of SEP-363856 in Patients With Schizophrenia\nEstimated pri
 mary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ulotaront#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07225712
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767903-857@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281025
DTEND;VALUE=DATE:20281026
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07767903)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults Wi
 th Generalized Anxiety Disorder\nEstimated primary completion: 25 October 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07767903
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759128-857@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281206
DTEND;VALUE=DATE:20281207
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07759128)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults Wit
 h Generalized Anxiety Disorder\nEstimated primary completion: 6 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07759128
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786454-857@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07786454)
DESCRIPTION:Ulotaront\, phase 3\, Generalized Anxiety Disorder.\nStudy: A T
 rial of the Safety and Tolerability of SEP-363856 in Adults With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 26 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ulotaront#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07786454
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
